Most Paragraph IV strategies dont fail because of patents. They fail because of predictability.
If youve built your growth plan around Paragraph IV, you already know the headline risk: litigation, stay delays, and the hard math of at risk launches. But…
Predictable by Design: How Brands Outmaneuver Your Paragraph IV Strategy Read Post »
The First-Filer Trap: Why 180-Day Exclusivity Fails Without a Supply-Chain Moat
Theres a quiet misconception in generic drug strategy: that winning the first-to-file litigation clock automatically wins the market.
Pharmaceuticals dont work like that….
The First-Filer’s Trap: Why 180-Day Exclusivity Fails Without a Supply Chain Moat Read Post »
Stop Chasing Blockbusters: The High-Margin World of Unloved Orphan Drug Patents
Most pharma investors still look for the same thing: the blockbuster tailwind. Big launch, big market, big headlines. Its familiarand comfortable.
But theres an overlooked …
Stop Chasing Blockbusters: The High-Margin World of Unloved Orphan Drug Patents Read Post »
Regulatory teams dont just file paperworkthey manage risk that can end up in court.
In most pharma companies, regulatory affairs and legal counsel operate in parallel lanes. Regulatory moves the dossier. Legal prepares for litigation. But when patent…
Why Your Regulatory Team Needs to Think Like Drug Patent Litigators Read Post »
Drug R&D is lateuntil you make patent intelligence early.
The most expensive word in biotech isnt breakthrough. Its unexpected.
Unexpected prior art. Unexpected litigation risk. Unexpected exclusivity cliffs. Unexpected freedom-to-operate (FTO) out…
Bioequivalence is the easy part. Freedom to Operate is the cliff.
In the pharmaceutical industry, its tempting to treat bioequivalence as the finish line. Show that your genericor your authorized copyperforms like the reference product in the body, and…
Why Bioequivalence Is the Easy Part and Freedom to Operate Is the Cliff Read Post »
Pharmas safe portfolio story is comfortinguntil you look at the filing math.
For years, many drug companies have pursued a defensible strategy in plain sight: reduce the cost of building patents, file less, and let the strong pieces carry the rest. Its…
The Safe Patent Portfolio Trap: Why Minimal Filing Costs Pharma a Decade of Growth Read Post »
Most Paragraph IV decisions dont fail because the science is wrong. They fail because the filing is sloppy.
In patent litigation, we tend to talk about winning as if its binaryright claim, wrong claim, enough evidence, not enough. But the unglamorous…
The At-Risk Launch: When the Math Says Go, Even if the Court Says No
Theres a particular moment in the drug lifecycle when corporate lawyers, economists, and commercial teams stop speaking the same languageand start speaking the same risk.
Its the mome…
The At-Risk Launch: When the Math Says Go, Even If the Court Says No Read Post »
Evergreening isnt a mythbut it is easy to mythologize.
Drugmakers, payers, regulators, journalists, and investors all use the term evergreening to describe how brand companies can extend market exclusivity beyond what many people think the original pat…
The Evergreening Myth: How to Spot the Cracks in a 20-Patent Thicket Read Post »
Get new actionable insights and updates from BiotechBlog
